| Company Name: |
DC Chemicals |
| Tel: |
021-58447131 13564518121 |
| Email: |
doncunbiosci@gmail.com |
|
| | Israpafant Basic information |
| Product Name: | Israpafant | | Synonyms: | Israpafant;Y 24180;4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine;Y-24180;Y24180;Israpafant
(Y-24180;6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-;7-(2-chlorophenyl)-9,13-dimethyl-4-[2-[4-(2-methylpropyl)phenyl]ethyl]-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene;Benzaldehyde,5-methoxy-4-nitro- | | CAS: | 117279-73-9 | | MF: | C28H29ClN4S | | MW: | 489.07 | | EINECS: | | | Product Categories: | | | Mol File: | 117279-73-9.mol |  |
| | Israpafant Chemical Properties |
| Melting point | 129.5-131.5° |
| | Israpafant Usage And Synthesis |
| Uses | Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca2+ influx and intracellular Ca2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice[1][2]. | | References | [1] Takehara S, et al. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors. Prostaglandins. 1990 Dec;40(6):571-83. DOI:10.1016/0090-6980(90)90002-d
[2] Jan C R, Chao Y Y. Novel effect of Y-24180, a presumed specific platelet activation factor receptor antagonist, on Ca2+ levels and growth of human prostate cancer cells. Cellular signalling, 2004, 16(8): 959-965. |
| | Israpafant Preparation Products And Raw materials |
|